To determine if TP53 and ARID1A co-alterations were associated with metastasis, we examined the MSK-IMPACT Clinical Sequencing Cohort of 10,501 primary or metastatic tumor samples with targeted mutation data [52]. The gene discussed is TP53; the disease is metastatic neoplasm.